Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 or older who have signed a written consent form to take part in the study.
• People with a good to near-normal level of physical functioning (able to carry out daily activities with little or no limitation).
• People with a life expectancy of at least 3 months.
• People who have been diagnosed with a specific type of high-grade ovarian, fallopian tube, or primary peritoneal cancer (including high-grade serous, clear cell, or grade 3 endometrioid types) that has come back after platinum-based chemotherapy.
• People whose cancer returned 6 or more months after finishing platinum-based chemotherapy, who have already received 3 or more lines of treatment, and for whom further platinum-based treatment is not considered appropriate.
• People whose cancer came back within 6 months of finishing platinum-based chemotherapy, who have received 3 or fewer previous lines of treatment.
• People whose cancer can be measured on scans, as assessed by the trial site team using standard criteria (RECIST v1.1).
• People who are able to provide a stored tumour tissue sample (a specific type called FFPE).
• People whose liver, kidneys, and other organs are functioning at an adequate level.
• People of reproductive potential who agree to use effective contraception during the study and for 6 months after the last dose of the study treatment.

Who may not be able to join:

• People whose ovarian cancer is of certain other types, such as mucinous, low-grade serous, carcinosarcoma, or sex cord stromal cell tumour.
• People who have cancer that has spread to the brain or the lining around the brain.
• People who have fluid build-up around the lungs, heart, or abdomen that cannot be controlled and requires repeated draining.
• People who have had another active cancer in the 3 years before joining the trial.
• People who have received systemic anti-cancer treatment within 3 weeks before joining the trial.
• People who have previously received any treatment that works by targeting the body's immune system to fight cancer.
• People who have had major surgery, an open biopsy, or a significant injury within 4 weeks before joining the trial, or who are expected to need major surgery during the study.
• People with an autoimmune disease that is currently active or likely to return.
• People who have needed regular steroid medication (above a certain dose) or other immune-suppressing medicines within 14 days before joining the trial.
• People who have received a live vaccine within 4 weeks before joining the trial.
• People with a known immune system deficiency, including those who test positive for HIV.
• People who have had an organ transplant or a stem cell transplant from a donor.
• People with a known history of scarring or inflammation of the lung tissue, or non-infectious lung inflammation.
• People who have had a serious infection requiring hospitalisation.
• People with a current active infection requiring systemic treatment.
• People with active hepatitis B or active hepatitis C infection.
• People with active or diagnosed inflammatory bowel disease or active diverticulitis.
• People with significant heart or brain blood vessel disease.
• People who still have unresolved side effects from previous cancer treatments.
• People with a history of severe allergic reactions to monoclonal antibody treatments.
• People who are pregnant or currently breastfeeding.
• People who, in the investigator's judgement, have any condition that could put them at risk from the study treatment.
• For certain groups within the trial (Cohorts 1, 2, and 4): People with known allergies or medical reasons preventing the use of specific chemotherapy drugs (PLD, paclitaxel, or topotecan).
• For certain groups within the trial (Cohorts 2, 3, and 4): People with known allergies to components of a specific study drug (AK112) or conditions that could affect their safety when receiving it (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.